



Published in final edited form as:

Cancer Prev Res (Phila). 2012 November ; 5(11): 1260–1272. doi:10.1158/1940-6207.CAPR-12-0140.

Obesity, Energy Balance and Cancer: *New Opportunities for Prevention*

Stephen D. Hursting¹, John DiGiovanni¹, Andrew J. Dannenberg², Maria Azrad³, Derek LeRoith⁴, Wendy Demark-Wahnefried³, Madhuri Kakarala⁵, Angela Brodie⁶, and Nathan A. Berger⁷

¹Department of Nutritional Sciences, University of Texas, Austin, Texas 78712, USA

²Weill Cornell Cancer Center, Weill Cornell Medical College, New York, NY10065, USA

³Department of Nutrition Sciences, University of Alabama at Birmingham, Birmingham, AL 35294 USA

⁴Metabolism Institute, Division of Endocrinology, Diabetes and Bone Disease, Mt Sinai School of Medicine, New York, NY 10029 USA

⁵Department of Internal Medicine, University of Michigan, Ann Arbor, MI 48109 USA

⁶Department of Pharmacology and Experimental Therapeutics, University of Maryland, Baltimore, Maryland 21201 USA

⁷Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH 44106 USA

Abstract

Obesity is associated with increased risk and poor prognosis for many types of cancer. The mechanisms underlying the obesity-cancer link are becoming increasingly clear and provide multiple opportunities for primary to tertiary prevention. Several obesity-related host factors can influence tumor initiation, progression and/or response to therapy, and these have been implicated as key contributors to the complex effects of obesity on cancer incidence and outcomes. These host factors include insulin, insulin-like growth factor-1, leptin, adiponectin, steroid hormones, cytokines, and inflammation-related molecules. Each of these host factors is considered in the context of energy balance and as potential targets for cancer prevention. The possibility of prevention at the systems level, including energy restriction, dietary composition and exercise is considered as is the importance of the newly-emerging field of stem cell research as a model for studying energy balance and cancer prevention.

Keywords

neoplasms; obesity; diet; growth factors; hormones

Introduction

The prevalence of obesity has doubled globally, reaching pandemic proportions over the past 30 years. Today, 65% of the world's population lives in countries where obesity kills far more people than underweight (1). Obesity increases the risk for colon, endometrial,

esophageal, renal, pancreatic and post-menopausal breast cancer, and the list continues to grow (2). More recent epidemiologic studies confirm the associations indicated above and provide probable evidence for associations of obesity with gallbladder and hepatocellular carcinomas (3,4), as well as suggestive evidence for associations with ovarian and thyroid cancers. Obesity is also associated with increased risk for several hematologic malignancies including plasma cell myeloma, Hodgkin and non-Hodgkin Lymphoma and leukemia (5, 6). Moreover, obesity at the time of diagnosis is acknowledged to be a poor prognostic factor for several tumor types (7). Although difficult to investigate or implement in humans, caloric restriction (CR) studies in multiple organisms have provided significant insights into the mechanistic links between energy balance and cancer and suggest novel approaches for interventional targets (8).

Many energy balance-related physiologic processes, including appetite, energy expenditure, body temperature control, and nutrient and energy metabolism are regulated by hormones, cytokines and other host factors. There is increasing evidence that alterations in, and cross-talk between cytokines and growth and inflammatory factors, e.g., insulin, insulin-like growth factor (IGF)-1, leptin, and adiponectin, mediate many of the antiproliferative, proapoptotic, and anticancer effects of CR or negative energy balance (8, 9). Given the universal need for energy, multiple pathways with ample crosstalk and redundancies have evolved to assure cell survival, regardless of whether cells are healthy, transformed, or cancerous. These pathways may be even more highly evolved in the preneoplastic or neoplastic cell to support increased energy needs for enhanced proliferation and uncontrolled cell growth (10).

Select proposed mechanisms that undergird energy balance effects on cancer were addressed by experts in a recent workshop, entitled “The Role of Obesity in Cancer Survival and Recurrence,” convened by the Institute of Medicine’s (IOM) National Cancer Policy Forum in Washington, DC (October 31-November 1, 2011). This article provides a summary of the mechanisms that were addressed and reframes this information to address their potential to serve as targets for cancer prevention; a transcript of this original workshop and accompanying slides are available online (11).

While controversy remains, the preponderance of clinical evidence supports a role for obesity’s influence on the incidence and course of many cancers (2–6) with strong support for potential mediators derived from preclinical mechanism-based studies which are further supported by clinical-epidemiologic observations. These preclinical, mechanistic studies are the major focus of this report with related clinical – epidemiologic research noted to provide translational relevance.

Overview

Figures 1 and 2 provide a systems overview of the multitude of extracellular and downstream intracellular pathways by which energy balance modulates cell growth, carcinogenesis and tumor promotion (12). Note that these multiple factors interact at numerous levels and share extensive cross-talk. Thus, attempts to block a pathway with a specific inhibitor may be undermined by collateral effects on alternate pathways. Therefore, targeting multiple pathways is likely to be necessary to develop prevention and control regimens that can effectively exploit the obesity-cancer linkage.

Hormones, Growth Factors and Intracellular Downstream Targets

Insulin

Clinical and epidemiologic evidence suggests that elevated levels of circulating insulin or C-peptide (cleavage product of proinsulin), are associated with increased risk and/or poor prognosis of endometrial, pancreatic, renal, prostatic, colon, and pre and postmenopausal breast cancers (9,12,13). Insulin exerts tumor-enhancing effects directly via the insulin receptor (IR) or hybrid IR/IGF-1R's on preneoplastic and neoplastic cells. High circulating levels of insulin also upregulate hepatic synthesis of IGF-1 and downregulate IGF binding protein (BP) production (13). The binding of insulin or IGF-1 to cell surface receptors activates the phosphatidylinositol-3 kinase (PI3K)/Akt pathway (leading to downstream activation of the mammalian target of rapamycin [mTOR] complex), and/or the mitogen-activated protein kinase (MAPK) pathway; both pathways are central regulators of cell growth and mitogenesis (9,12)

In a mouse model of hyperinsulinemia, mammary tumor growth and metastasis is enhanced by endogenous hyperinsulinemia activating the IR/IGF-1Rs on tumor cells. Reducing hyperinsulinemia and blocking IR/IGF-1R activation with a specific tyrosine kinase inhibitor, decreases tumor burden (14, 15). These data strongly suggest that endogenous hyperinsulinemia may be one obesity-related factor enhancing cancer growth and metastases. Moreover, in women with breast cancers, a worse prognosis was noted in those with higher circulating insulin level as well as those with increased insulin receptor expression in tumor tissue (16).

The effect of insulin on cancer cells has furthermore been shown to activate an IR subtype (IR-A) that is expressed by fetal tissues and cancer cells. IR-A mediates insulin's metabolic functions and is more mitogenic than the other splice variant, IR-B, expressed in muscle, fat and liver (17).

The presence of IR-A on tumor cells may provide a specific target to block insulin stimulation of cancer cell growth without interfering with its normal role in energy metabolism. Targeting the intracellular PI3K-Akt pathway, downstream of the insulin receptor, also may provide an alternative approach to specifically interrupt the growth promoting activities of insulin associated with hyperinsulinemia and insulin resistance.

Insulin-like Growth Factor-1 (IGF-1)

IGF-1 is a major endocrine and paracrine regulator of tissue growth and metabolism since it both suppresses apoptosis and initiates cell cycle progression from G1 to S phase by activating PI3K/Akt and MAPK signal transduction pathways and modulating cyclin-dependent kinases (13). Epidemiologic evidence also supports the hypothesis that increased circulating IGF-1 is associated with increased risk and/or worse prognosis for several types of human cancers (8, 18). IGF-1 may act either directly on cells via IGF-1Rs or IRs (or even IGF/IR hybrid receptors), or indirectly through interaction with other cancer-related molecules, e.g., the tumor suppressor, p53 (13). In numerous animal models, obesity increases, while CR decreases circulating IGF-1 and tumor development and progression (8, 9, 19) whereas exogenous IGF-1 infusion rescues tumor growth in CR mice (8, 18). Similar to CR, genetic reduction of circulating IGF-1 in liver-specific IGF-1 deficient mice decreases tumor progression in models of colon, skin, mammary and pancreatic cancer (20,21). Interestingly, IGF-1 deficient mice, which are resistant to growth of several tumor types, have markedly elevated insulin and adipokine levels, but a 65% reduction in IGF-1 (22), suggesting that IGF-1 may be a central determinant of energy balance modulation of cancer in experimental models (8). However, the obesity-IGF-1 relationship is more complex in humans, as total circulating IGF-1 levels are often not elevated in obese

individuals (23, 24). The hyperinsulinemia associated with obesity can decrease production of IGF binding proteins (particularly BP1 and 2), and thus increase the levels of bioavailable IGF-1 to enhance signaling through the IGF-1R (13). Agents that block the IGF-1R to decrease IGF-1 signaling, and to some extent insulin signaling are under clinical development and may serve as cancer prevention and control agents; however selectivity for tumor cells and unwanted metabolic effects remain a challenge for these agents (25).

Vascular endothelial growth factor (VEGF)

VEGF is induced by insulin and IGF-1 (26), and mediates cancer cell proliferation and tumor growth by inducing angiogenesis. Produced by both adipocytes and tumor cells, higher circulating levels of VEGF are seen in obese animals (27) and humans (28), and decrease upon weight loss (29). A recent and growing body of evidence in humans suggests strong associations between VEGF levels and aggressive cancers (30,31). Several tyrosine kinase inhibitors that interfere with VEGF activity have been developed and could play a role in cancer prevention.

Steroid hormones

Estrogen

Estrogen is produced in large amounts by the ovary via conversion of androgens (testosterone and androstenedione) in a reaction mediated by aromatase. After menopause when the ovary ceases to function, estrogens continue to be produced by other tissues, with a major contributor being adipose tissue. Multiple lines of evidence suggest a key role for estrogen in explaining the increased risk of hormone receptor-positive breast cancer in obese postmenopausal women. Estrogen has also been implicated in the pathogenesis of a subset of endometrial cancers arising in obese women (32). Total and free estrogen levels are increased in the plasma of obese compared to normal weight postmenopausal women (33). Estrogen binds to estrogen receptor α and thereby stimulates cell proliferation and inhibits apoptosis (34). Estrogens can also induce VEGF and angiogenesis (35). In addition to driving tumor formation via estrogen receptor α -dependent effects, estrogen can be metabolized into DNA reactive metabolites that potentially induce mutagenesis (34). There is clear evidence of the growth promoting effects of estrogens from studies in animals (36). The importance of targeting estrogen as a preventive intervention is underscored by clinical data. Tamoxifen and raloxifene, functioning as selective estrogen receptor modulators, have been shown to significantly reduce the development of postmenopausal breast cancer (37) and these agents are effective secondary preventive agents in women who have undergone primary treatment for breast cancer (38). Raloxifene has also been shown to have a preventive effect on the development of uterine cancer (39). Recently, treatment with Exemestane, an aromatase inhibitor, was found to decrease the relative risk of invasive breast cancer by 65% (40). Notably, many of the women enrolled in this trial were overweight or obese.

A major unanswered question concerns the relative importance of peripheral vs. breast adipose tissue as the primary source of the estrogen that drives tumor formation and progression in obese postmenopausal women. Until recently, it was assumed that the mildly elevated levels of estrogen in venous blood of obese vs. lean postmenopausal women could account, in part, for the observed increased risk of breast cancer. However, two recent findings have challenged this explanation. First results from the Women's Health Initiative Estrogen-Alone Trial indicate that administration of estrogen only hormone replacement therapy was associated with a lower incidence of invasive breast cancer in postmenopausal women among those who have had previous hysterectomy(41). Second, as detailed below, obesity was recently found to cause breast inflammation, elevated aromatase levels and

activation of estrogen receptor- α -dependent gene expression (42, 43, 44). Collectively, these recent findings highlight the complexity of estrogen biology but offer clues to the development of future preventive strategies.

Testosterone and Other Androgens

The role of androgens in prostate cancer is significant since estimates indicate that 80–90% of prostate cancer is dependent on circulating androgens for growth (45) and androgen deprivation directly or through administration of LHRH antagonists, is a highly successful mainstay of anti-prostate cancer therapy (46). However, it is difficult to describe how obesity, androgen exposure and prostate cancer risk are inter-related since obesity is associated with lower circulating levels of androgens in men (47), and there is no strong association between obesity and prostate cancer risk overall (48). However, there is a significant association between obesity and aggressive prostate cancer (49), which may relate to the cross-talk between androgens and circulating cytokines (e.g., IL-6) and growth factors (e.g., IGF-1 and EGF) which can activate the androgen receptor and stimulate JAK/STAT and the PI3k/Akt/mTOR pathways, respectively (50), or the overexpression and loss of specificity of the androgen receptor which then promiscuously binds ligands driving cell survival and proliferation (50).

Adipokines

Leptin and adiponectin are pleiotropic adipocytokines produced and secreted by adipose tissue. As body fat stores increase, circulating leptin concentrations increase whereas adiponectin levels decrease. The obesity-driven imbalance in adiponectin and leptin are considered key factors linking obesity and cancer. Both mediate energy intake by functioning as neuroendocrine signaling hormones that regulate dietary intake (51,52), metabolism, insulin sensitivity, and inflammation (53,54–55). Adiponectin and leptin have direct tumor effects regulating both cell proliferation and apoptosis (56).

Leptin

Six leptin receptors have been identified (ObRa-ObRf); however, only ObRb has a functioning intracellular signaling domain. *In vitro* studies have shown that activation of ObRb by leptin stimulates cell proliferation and survival in colon (57,58), breast (59), endometrial (60) and androgen-independent prostate cancer cells (61). Leptin signaling is executed through activation of several pathways including JAK/STAT3, PI3k/Akt and ERK 1/2 (62) and these pathways all serve as potential targets for cancer prevention and control. Leptin also transactivates the EGFR, Notch, and Survivin pathways, and stimulates tumor invasion and migration (63). Leptin can modulate tumor growth by increasing expression of VEGF, a key driver of angiogenesis (64). In animal models, leptin deficiency inhibits mammary tumor growth (65), whereas higher levels are promotional (66). Using azoxymethane to induce colon carcinogenesis in mice, Endo and colleagues showed that leptin signaling through STAT3 resulted in significantly higher tumor proliferation and growth, whereas leptin deficient mice had significantly lower proliferation and smaller tumors despite being more obese (67). In contrast, Ribeiro et al. inoculated mice with RM-1 murine androgen independent prostate cancer cells and found that higher leptin concentrations did not increase prostate cancer tumor growth (68). Thus, disparate effects have been observed across cancer types.

In epidemiological studies, the link between leptin and cancer has also proven inconsistent. In a nested case-control study in Japanese women, leptin was significantly associated with colorectal cancer after adjusting for several risk factors including BMI (69). In contrast, a case-control study in the US did not find an association between leptin and colorectal

adenoma risk in women, but did observe a 3-fold increased risk among men when comparing the highest tertile against the lowest (70). Gender differences in leptin-related risk for colorectal cancer also have been observed (71). Likewise, the data on leptin and risk for breast cancer are conflicting with one study reporting a positive association (72) whereas others reported no association (73,74), or an inverse association (confined to premenopausal breast cancer) (75). In endometrial cancer, a positive association with leptin was found for two studies, though in one this relationship disappeared after adjusting for BMI (76,77). For prostate cancer, leptin does not appear to increase overall risk (78,79, 80) however, it may be linked with more aggressive disease (81). In addition, recent studies suggest that absolute levels of leptin may not be the driving force behind neoplasia, but rather it is the ratio of higher leptin in the presence of low adiponectin that confers risk (82).

Adiponectin

There are two receptors for adiponectin, AdipoR1 and AdipoR2, which are expressed ubiquitously. Binding of adiponectin to its receptors stimulates phosphorylation of AMPK, a nutrient-sensing enzyme which regulates several key pathways involved in cellular energy metabolism and protein synthesis (83). *In vitro*, adiponectin induces apoptosis (84), and inhibits growth and proliferation of breast (85,86,87), colon (88), endometrial (84), and androgen dependent and independent prostate cancer (89). Adiponectin also sequesters several circulating growth factors (90) and inhibits angiogenesis by inducing apoptosis of endothelial cells (91). Studies using preneoplastic murine colon cells have shown that adiponectin inhibits leptin and IL-6 induced cell proliferation by blocking activation of NFkB and STAT3 (92). Similarly, in late stage colon cancer cells, adiponectin inhibits IL-6 induced cell proliferation (93). Many, but not all (94) studies using animal models have shown that lower adiponectin results in increased colon tumor growth (95). Interestingly, in the mouse mammary tumor virus (MMTV)-polyoma middle T antigen (PyMT) mammary tumor model, adiponectin-deficient mice have reduced onset and size of mammary tumors as a result of reduced angiogenesis compared to wild-type mice (96, 97).

Data from epidemiological investigations suggest a role for adiponectin in reducing the risk of several cancers. Consistent with *in vitro* studies, but in contrast to animal models, a consistent association between higher adiponectin concentrations and decreased risk for postmenopausal breast cancer, as well as disease recurrence and mortality has been found repeatedly (98,99,100,101,102). Most studies have also reported that higher adiponectin levels are associated with lowered risk for endometrial cancer (102,103,104,105). A recent meta-analysis of 13 studies examined the association between adiponectin and colorectal cancer and adenomas and found a significant reduction in risk for men, but not for women (106). For prostate cancer, the data are conflicting and may reflect discrepant associations in aggressive vs. indolent disease (107,108).

Intracellular Pathways

PI3K/Akt/mTORC1

Rapamycin, a CR mimetic and potential chemopreventive agent, effectively blocks mTORC1 complex formation, thus inhibiting mTORC1-mediated cellular growth and proliferation (109,110), and has been shown to extend lifespan in mice (111). Furthermore, rapamycin has been shown to suppress tumorigenesis in several animal models (112, 113, 114, 115,116), and inhibits tumor promotion by blocking mTORC1 signaling through p70S6K, and cell cycle proteins PCNA and cyclin D1 (117). Rapamycin also exerts anti-inflammatory effects, and reduces TPA-induced infiltration of several types of inflammatory cells (118). Collectively, these findings suggest that rapamycin may function as a potent compound in cancer prevention. EGFR activation likewise is modulated by caloric intake

and may also influence Akt and mTORC1 signaling, and EGFR activation via IGF-1R/EGFR cross-talk (119).

5'Adenosine Monophosphate – Activated Protein Kinase (AMPK)

Under conditions of CR, mTORC1 signaling is inhibited, leading to cell growth arrest, inhibition of protein translation, and autophagy (119, 120). AMPK and the upstream kinase, LKB1, function to repress mTORC1 in the presence of negative energy balance through activation of TSC1/2. Low ATP/AMP ratios activate AMPK, and phosphorylation is maintained by LKB1 (121). Activation of this pathway not only reduces cellular energy expenditure, but it also protects against stress-induced apoptosis. Studies using *in vivo* models provide evidence that the anti-diabetic drug, metformin which inhibits gluconeogenesis through indirect activation of AMPK, can inhibit tumor formation. Administration of metformin suppresses polyp formation in *Apc/Min* mice (122). Using paired isogenic colon cancer cell lines (HCT116 p53^{+/+} or P53^{-/-}), Buzzai et al (123) were able to show that metformin inhibited the growth of xenograft tumors derived from the p53 null cell line. Also, daily exposure to metformin attenuated tumorigenesis (lymphoma; intestinal polyps) in PTEN-deficient mice (124).

Epidemiological studies have suggested that diabetic patients receiving metformin have significantly reduced cancer burden compared with diabetic patients receiving other therapies (125). Recent studies have also suggested that metformin may be more effective in overweight/obese individuals or in individuals with elevated insulin levels (12), and clinical trials are now underway to evaluate the effect of metformin for the prevention of recurrence of breast cancer.

Immune Cells and Inflammatory Factors

Macrophage infiltration

Chronic inflammation has long been associated with cancer development and progression and increases the risk of multiple tumor types (9). Obesity leads to subclinical inflammation in visceral and subcutaneous white adipose tissue (WAT), characterized by macrophages surrounding necrotic adipocytes and forming crown-like structures (CLS) (126, 127, 128). Increased numbers of CLS were demonstrated within the mammary glands of obese mice, accompanied by activation of NF κ B, increased levels of pro-inflammatory mediators, and higher levels and activity of aromatase and its activity, thus driving the synthesis of estrogen (and perhaps ER⁺ breast cancer) (42). These findings support the possibility that the obesity→inflammation axis is important for breast carcinogenesis.

In women, CLS of the breast (CLS-B) were found in nearly 50% of patient samples (43). The severity of breast inflammation, defined as the CLS-B index, correlated with BMI and adipocyte size, and may serve as a biomarker of increased breast cancer risk or poor prognosis. Consistent with the preclinical findings, increased NF κ B binding activity, increased levels of pro-inflammatory mediators, and elevated aromatase expression and activity were found in the inflamed breast tissue of overweight and obese women (43, 44). The discovery of the connection between obesity, breast inflammation and changes in the expression of genes linked to breast cancer suggests the possibility that interventions which reduce breast inflammation may decrease the increased risk of breast cancer in obese postmenopausal women.

Cytokines

Increasing adiposity has been shown to be positively associated with inflammation in both rodents and humans (129). The increased adipose tissue associated with obesity, especially

WAT produces many inflammatory cytokines, including tumor necrosis factor alpha (TNF- α), IL-6, IL-1 β , monocyte chemoattractant (MCP-1), and C-reactive protein, which act both locally (tissue level) and globally (circulating in serum) (130). Increased adipose-derived cytokine production, particularly increased levels of MCP-1, enhances local macrophage infiltration, leading to further increases in the levels of secreted inflammatory cytokines, as well as heightened recruitment of other related immune cells (130,131,132). These inflammatory cytokines modulate inflammation via increased intracellular signaling through NF κ B-, STAT3-, and JNK-related pathways (130,133), events which are inhibited by CR (134). These findings suggest the possibility that diet induced changes in inflammation may modulate tumor development and progression.

NF κ B

At the intracellular level, inflammation is mediated through multiple pathways. NF κ B is a transcription factor activated in response to various stimuli including growth factors and inflammatory molecules, and is responsible for inducing gene expression associated with cell proliferation, apoptosis, angiogenesis and inflammation (135). Activation of NF κ B has been observed in many tumor types, and has emerged as an important target for cancer drug development (136). Obesity and CR modulate NF κ B activation, possibly through alterations in growth factors and Akt signaling (135,137). Activation of NF κ B by Akt can lead to the translocation of the active NF κ B subunit, p65, from the cytoplasm to the nucleus, inducing multiple genes associated with inflammation and cancer, including IL-6, COX-2, and IL-1 β (135). Thus, NF κ B represents an attractive drug target for attempting to reduce the risk or progression of cancer.

Systems Level Considerations

Diet Composition

While there is a clear association between obesity and cancer in both humans and animal models, it is frequently difficult to distinguish the consequences of diet composition from those of obesity. Studies in humans, largely based on observational research, especially those on international differences in dietary fat consumption and cancer incidence, as well as, on a limited number of case control studies, are suggestive of an association between dietary fat and increased risk of breast, colorectal and prostate cancers. However results of these studies are mixed and confounded by body weight status (138,139, 140). In addition, two large randomized control trials, The Women's Healthy Eating and Living (WHEL) Study (141) and The Women's Intervention Nutrition Study (WINS) (142) evaluated the effect of dietary modification on cancer recurrence and survival in women with early stage breast cancer. The WINS study reported borderline significance for an association between dietary fat and "breast cancer events", whereas the WHEL study found no significant association between fat and breast cancer recurrence, (141,142, 143). Comparison of these studies is confounded by multiple differences, among which is the ability to separate the reduction in dietary fat from weight loss (141,142,143).

To investigate the individual contribution and to bypass the confounding issues associated with genetics, dietary fat and obesity experiments were conducted capitalizing on the observation that C57BL/6 mice fed a high fat diet become obese, whereas A/J mice fed the same diet remain lean. Taking advantage of these genetic differences, a series of crosses were performed between the B6 and A/J mice to generate chromosome substitution strains (CSSs) of mice in which each pair of homozygous A/J chromosomes were substituted on an otherwise B6 genetic background (144). These CSSs provide a series of B6 strains that are susceptible or resistant to diet-induced obesity based on a single pair of A/J chromosomes. Further research has focused on separating the effect of dietary fat from obesity, using CSSs

in combination with B6. $Apc^{Min/+}$ mouse models of intestinal cancer were employed to generate Congenic-Consomic Strains (C-CSs). Employing C-CSs that were susceptible to $Apc^{Min/+}$ intestinal tumors and were either susceptible or resistant to diet-induced obesity depending on the substituted A/J chromosome, it was shown that a high-fat diet vs. low-fat diet (58% vs. 10%) resulted in significant increases in intestinal polyp numbers, tumor burden, and shorter survival time independent of obesity. Moreover, mice fed the high-fat diets showed increases in inflammatory cytokines in the sera (IL-6, and IL-1 β), and in intestinal tissue (TNF α , Cox-2, IL-1 β and IL-6). These studies clearly demonstrate that a high-fat diet, independent of obesity, can upregulate intestinal and circulating inflammatory mediators, and increase intestinal polyp growth and tumor burden leading to shorter survival (145). These studies support the use of low fat diets as a cancer prevention strategy, at least for some cancer types, and suggest that anti-inflammatory agents may also be useful in preventing high fat diet induced carcinogenesis. In view of the WINS and WHEL trials, these studies with mouse CSSs point to the need for randomized controlled trials of dietary fat modification for primary prevention, especially since the WHI study showed that the low-fat diet resulted in a reduction in primary breast cancer of borderline significance (146), and significantly reduced ovarian cancer (147). Moreover, diet studies during critical windows of susceptibility along the lifecourse are needed. In particular, studies occurring during the critical periods associated with breast bud development in the early years of life also are needed.

Exercise

As recently reviewed, exercise interventions have been associated with reduced risk of some types of cancer in humans, with convincing evidence that the exercise-cancer link is independent of body weight status for colon, breast and endometrial cancers; weak evidence for prostate, lung and ovarian; and either null or insufficient data for other cancer types (148). Studies examining the effects of exercise on carcinogenesis have used a variety of animal models and many, but not all, studies report some evidence of a protective effect of either voluntary or involuntary exercise on carcinogenesis. The strength and direction of the association depend on cancer type, intensity of the exercise regimen and whether food intake was held constant or provided *ad libitum*. Thompson and colleagues recently reported that plasma markers with the greatest predictive value of the anticancer effects of both moderate CR and moderate exercise in a carcinogen-induced rat mammary model were adiponectin, bioavailable IGF-1, and leptin (149). In other models, exhaustive exercise has been linked to increased reactive oxidative stress and inflammation, and increased tumor development (150), while moderate exercise can often be anti-inflammatory (151). Given the inherent links between exercise and energy balance, the effects of exercise per se, independent of decreased energy balance, remain unclear. A study of gene expression profiles in normal mammary tissues of 9 week old C57BL/6 mice that were randomized to caloric restriction and/or exercise however suggests that pathways may differ considerably since caloric restriction modified gene expression in 425 genes, whereas physical activity modified expression in just 45, with overlap noted in only 3 genes (152). Results of recent clinical trials in healthy volunteers suggest that weight loss may exert a more powerful effect on biomarkers associated with inflammation and sex steroid pathways (153, 154). Recent studies in mice demonstrate that exercise reduces systemic insulin resistance by an autophagy-inducing process. The latter could provide a mechanism for exercise to reduce tumor growth through a process of reduced levels of circulating insulin (155).

Cancer Stem Cells

Cancer stem cells, their role in carcinogenesis and progression, and their potential as targets for cancer prevention and therapy, has become a major focus of cancer research. Moreover, as described below, cancer stem cells may provide targets for some of the proliferation

stimulating effects of adipocytokines elevated in obesity. Tissue stem cells are a population of cells with the capacity to undergo self-renewal and multilineage differentiation into the normal cell population that constitute tissues and organs. The cancer stem cell hypothesis postulates that tumors originate through dysregulation of the normal self-renewal process resulting in the aberrant replication and differentiation characteristic of a variety of tumors. Clonal expansion of these aberrant cells has recently been confirmed by lineage tracing in mouse intestinal adenomas (156) and is an early step in carcinogenesis. In addition to being responsible for primary tumorigenesis, the cancer stem cells may be resistant to chemotherapeutic agents and responsible for tumor recurrence and metastasis. Thus, strategies aimed at limiting proliferation of these stem cells may be useful for both primary and secondary cancer prevention.

A new linkage between obesity and tumor stem cells has recently been identified by Zheng et al. (65) who showed that spontaneous tumors derived from murine mammary tumor virus-Wnt-1 transgenic mice, when transplanted, were highly leptin-dependent for growth. Thus, transplantation of these tumors into obese, leptin receptor deficient mice (db/db) with high leptin concentrations, grew to 8 times the volume of those tumors transplanted into wild-type mice, while in leptin-deficient (ob/ob mice) tumor growth and overall tumor burden was reduced. The residual tumors in ob/ob mice were found to have fewer "stem cells" and these cells were characterized by flow cytometry to express LepRb (65). When isolated by LepRb expression, these cells exhibited stem cell properties of tumorsphere formation in vitro, and their survival was regulated by leptin. Dunlap, et al report that M-Wnt mammary tumor cells derived from Wnt-1 tumor profile with human claudin-low breast tumors, are mesenchymal and stably enriched in breast cancer cell markers, and exhibit stem cell properties (157). In addition, M-Wnt cells orthotopically injected into B6 mice rapidly form claudin-low tumors that are highly responsive to the tumor enhancing effects of obesity, as well as the anticancer effects of calorie restriction (157). Relationships between obesity, adipose tissue cytokines, and stem cell biology also can be readily studied in vitro directly from human breast tissue excised during elective reduction mammoplasty (158). However, at present, human clinical trials specifically targeting stem cells are hampered by the need for large volumes of breast tissue (e.g., from mammoplasty or mastectomy) for stem cell isolation and dynamic assays such as in vitro tumor sphere formation as biomarker endpoints (159). Therefore, current efforts are focused upon using core biopsy samples for stem cell isolation and characterization using advanced in situ technologies, such as multiplex imaging or profiling technologies.

Conclusions and Future Directions

While much current research focuses on selected signaling pathways, this review emphasizes the numerous mediators and pathways by which obesity impacts cancer. Many of the circulating signaling molecules bind to cell surface receptors where they activate intracellular pathways which undergo cross-talk and activate intracellular downstream pathways that both converge and diverge to promote cancer cell growth and metastasis.

These observations suggest several strategies for prevention and therapy of obesity mediated cancer promotion including 1) prevention and treatment of obesity; 2) blocking synthesis and release of the signaling molecules including hormones, cytokines and adipokines; 3) blocking binding and activation of direct targets including cell surface and hormone receptors; 4) blocking downstream intracellular pathways such as the P13K, Akt, mTOR pathway; and 5) disrupting inflammatory pathways at both the cellular and systemic levels. This list might suggest that it should be easy to prevent cancer by blocking one or several of these pathways. However, Table 1 provides a partial list of 14 of the manifold obstacles to prevention of obesity associated cancers. These obstacles are divided into two major categories; the first being obstacles to disrupting obesity promotion of cancer, and the

second being obstacles to obesity control. Most of the factors listed in the first group have been discussed above in terms of defining their role in mediating the effect of obesity on cancer. The plethora of pathways connecting obesity to cancer suggests that while targeting any one of these pathways may provide potential interference with cancer cell growth, the cancer cell has established alternative and redundant processes and pathways to evade control and bypass road blocks at any one site. Thus, an important area for future research is to determine how to control obesity, as well as its downstream effects. Innovative approaches to these issues are imperative as are mechanistic studies and clinical trials on the effects of caloric restriction, exercise and potential pharmacomimetics of these processes.

With regard to the second group, obesity control is obviously critically important to multiple disorders, but a careful review of issues related to obesity prevention or reversal is beyond the scope of this article. Nonetheless, several of the major obstacles involved in its prevention and control are listed since they must be dealt with in any approach to disrupt the linkage between obesity and cancer.

Just as prevention and control of diabetes, hypertension and cardiovascular disease require multi-factor and multi-level approaches, including diet, physical activity, and behavioral modification, as well as pharmacologic and surgical interventions for subsets of individuals, so too it is likely that multipronged, transdisciplinary approaches will be required to disrupt the obesity-cancer linkage. The recent estimate that the incidence of obesity in the US will reach 42% by 2030 emphasizes the urgent need for this research (160).

Acknowledgments

Financial Support: Research reported in this review was supported by grants P30ES007784 and RO1CA129409 to SDH; RO1CA037111 to JD; RO1CA154481, Breast Cancer Research Foundation, the Botwinick-Wolfensohn Foundation (in memory of Mr. and Mrs. Benjamin Botwinick) to AJD; RO1CA128700 to DL; RO1CA062483 to AB; KO7CA128884 to MK; P30 CA13148 to MA and WDW, and U54 CA116867 and P40 RR012305 to NAB

References

1. [Accessed February 6, 2011.] WHO fact sheet 311. <http://www.who.int/mediacentre/factsheets/fs311/en/>
2. Calle EE, Kaaks R. Overweight, Obesity and cancer: epidemiological evidence and proposed mechanisms. *Nat Rev Cancer*. 2004; 4(8):579–91. [PubMed: 15286738]
3. Ballard-Barbash, R.; Berrigan, D.; Potischman, N.; Dowling, E. Obesity and Cancer Epidemiology. In: Berger, NA., editor. *Energy Balance and Cancer*. Springer; 2010. p. 1-44.
4. Nock, NL. Obesity and Gastrointestinal Cancers: Epidemiology. In: Markowitz, SD.; Berger, Na, editors. *Energy Balance and Gastrointestinal Cancer*. Springer; 2012. p. 1-22.
5. Teras, LR.; Patel, AV. The Epidemiology of Obesity and Hematologic Malignancies. In: Mittelman, SD.; Berger, NA., editors. *Energy Balance and Hematologic Malignancies*. Springer; 2012. p. 1-30.
6. Beason, T.; Colditz, G. Obesity and Multiple Myeloma. In: Mittelman, SD.; Berger, NA., editors. *Energy Balance and Hematologic Malignancies*. Springer; 2012. p. 71-95.
7. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospective studied cohort of U.S. adults. *N Engl J Med*. 2003; 48(17):1625–38. [PubMed: 12711737]
8. Hursting SD, Smith SM, Lashinger LM, Harvey AE, Perkins SN. Calories and carcinogenesis: lessons learned from 30 years of calorie restriction research. *Carcinogenesis*. 2010; 31:83–9. [PubMed: 19969554]
9. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. *J Clin Oncol*. 2010; 28:4058–65. [PubMed: 20697088]
10. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. *Science*. 2009; 324:1029–33. [PubMed: 19460998]

11. <http://www.iom.edu/Reports/2012/The-Role-of-obesity-in-Cancer-Survival-and-Recurrence.aspx>
12. Nock, N.; Berger, NA. Obesity and Cancer, Overview of Mechanisms. In: Berger, NA., editor. Energy Balance and Cancer. Springer; 2010. p. 129-179.
13. Pollak M. Insulin and insulin-like growth factor signaling in neoplasia. *Nat Rev Cancer*. 2008; 8:915–28. [PubMed: 19029956]
14. Dool CJ, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, et al. IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer. *Endocr Relat Cancer*. 2011; 18:699–709. [PubMed: 21946410]
15. Fierz Y, Novosyadlyy R, Vijayakumar A, Yakar S, LeRoith D. Insulin-sensitizing therapy attenuates type 2 diabetes-mediated mammary tumor progression. *Diabetes*. 2010; 59:686–93. [PubMed: 19959755]
16. Goodwin PJ, Ennis M, Pritchard KI, Trudeau ME, Koo J, Madarnas Y, et al. Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. *J Clin Oncol*. 2002; 20:42–51. [PubMed: 11773152]
17. Ferguson RD, Novosyadlyy R, Fierz Y, Alikhani N, Sun H, Yakar S, et al. Hyperinsulinemia enhances c-Myc-mediated mammary tumor development and advances metastatic progression to the lung in a mouse model of type 2 diabetes. *Breast Cancer Res*. 2012; 14:R8. [PubMed: 22226054]
18. Hursting SD, Lavigne JA, Berrigan D, Perkins SN, Barrett JC. Calorie restriction, aging, and cancer prevention: mechanisms of action and applicability to humans. *Annu Rev Med*. 2003; 54:131–52. [PubMed: 12525670]
19. Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D. The pathway from diabetes and obesity to cancer, on the route to targeted therapy. *Endocr Pract*. 2010; 16:864–73. [PubMed: 20841312]
20. Moore T, Carbajal S, Beltran L, Perkins SN, Yakar S, Leroith D, et al. Reduced susceptibility to two-stage skin carcinogenesis in mice with low circulating insulin-like growth factor I levels. *Cancer Res*. 2008; 68:3680–8. [PubMed: 18483250]
21. Harvey AE, Lashinger LM, Hursting SD. The growing challenge of obesity and cancer: an inflammatory issue. *Ann N Y Acad Sci*. 2011; 1229:45–52. [PubMed: 21793838]
22. Yakar S, Liu JL, Fernandez AM, Wu Y, Schally AV, Frystyk J, et al. Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. *Diabetes*. 2001; 50:1110–8. [PubMed: 11334415]
23. Alderete TL, Byrd-Williams CE, Toledo-Corral CM, Conti DV, Weigensberg MJ, Goran MI. Relationships between IGF-1 and IGFBP-1 and adiposity in obese African-American and Latino adolescents. *Obesity*. 2011; 19:933–8. [PubMed: 20885383]
24. Berrigan D, Potischman N, Dodd KW, Hursting SD, Lavigne J, Barrett JC, et al. Race/ethnic variation in serum levels of IGF-I and IGFBP-3 in US adults. *Growth Horm IGF Res*. 2009; 19:146–55. [PubMed: 18812263]
25. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials--early lessons. *J Mammary Gland Biol Neoplasia*. 2008; 13:471–83. [PubMed: 19023648]
26. Miele C, Rochford JJ, Filippa N, Giorgetti-Peraldi S, Van Obberghen E. Insulin and insulin-like growth factor-I induce vascular endothelial growth factor mRNA expression via different signaling pathways. *J Biol Chem*. 2000; 275:21695–702. [PubMed: 10777488]
27. Miyazawa-Hoshimoto S, Takahashi K, Bujo H, Hashimoto N, Yagui K, Saito Y. Roles of degree of fat deposition and its localization on VEGF expression in adipocytes. *Am J Physiol Endocrinol Metab*. 2005; 288:E1128–36. [PubMed: 15613686]
28. Loebig M, Klement J, Schmoller A, Betz S, Heuck N, Schweiger U, et al. Evidence for a relationship between VEGF and BMI independent of insulin sensitivity by glucose clamp procedure in a homogenous group healthy young men. *PLoS One*. 2010; 5:e12610. [PubMed: 20830305]
29. Heymach JV, Shackelford TJ, Tran HT, Yoo SY, Do KA, Wergin M, et al. Effect of low-fat diets on plasma levels of NF- κ B-regulated inflammatory cytokines and angiogenic factors in men with prostate cancer. *Cancer Prev Res*. 2011; 4:1590–8.
30. Liu Y, Tamimi RM, Collins LC, Schnitt SJ, Gilmore HL, Connolly JL, et al. The association between vascular endothelial growth factor expression in invasive breast cancer and survival

- varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses' Health Study. *Breast Cancer Res Treat.* 2011; 129:175–84. [PubMed: 21390493]
31. Cao D, Hou M, Guan YS, Jiang M, Yang Y, Gou HF. Expression of HIF-1 α and VEGF in colorectal cancer: association with clinical outcomes and prognostic implications. *BMC Cancer.* 2009; 9:432. [PubMed: 20003271]
 32. Ulrich LSG. Endometrial cancer, types, prognosis, female hormones and antihormones. *Climacteric.* 2011; 14:418–425. [PubMed: 21426234]
 33. Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Longcope C, et al. Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. *J Natl Cancer Inst.* 2003; 95:1218–26. [PubMed: 12928347]
 34. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. *N Engl J Med.* 2006; 354:270–82. [PubMed: 16421368]
 35. Pequeux C, Raymond-Letron I, Blacher S, Boudou F, Adlanmerini M, Fouque MJ, et al. Stromal estrogen receptor- α promotes tumor growth by normalizing an increased angiogenesis. *Cancer Res.* 2012; 72:1–10.
 36. Brodie AM, Marsh D, Brodie HJ. Aromatase inhibitors--IV. Regression of hormone-dependent, mammary tumors in the rat with 4-acetoxy-4-androstene-3,17-dione. *J Steroid Biochem.* 1979; 10:423–9. [PubMed: 109701]
 37. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA.* 2006; 295:2727–4124. [PubMed: 16754727]
 38. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. *Lancet.* 2005; 365:1687–717. [PubMed: 15894097]
 39. DeMichele A, Troxel AB, Berlin JA, Weber AL, Bunin GR, Turzo E, et al. Impact of raloxifene or tamoxifen use on endometrial cancer risk: a population-based case-control study. *J Clin Oncol.* 2008; 26:4151–9. [PubMed: 18757329]
 40. Goss PE, Ingle JN, Ales-Martinez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. *N Engl J Med.* 2011; 364:2381–91. [PubMed: 21639806]
 41. LaCrois AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy. *JAMA.* 2011; 305:1305–14. [PubMed: 21467283]
 42. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. *Cancer Prev Res.* 2011; 4:329–46.
 43. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. *Cancer Prev Res.* 2011; 4:1021–9.
 44. Subbaramaiah K, Morris PG, Zhou ZK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. *Cancer Discov.* 2012; 2:356–365. [PubMed: 22576212]
 45. Heinlein CA, Chang C. Androgen receptor in prostate cancer. *Endocr Rev.* 2004; 25:276–308. [PubMed: 15082523]
 46. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR, et al. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). *Cancer.* 2006; 106:1708–14. [PubMed: 16544313]
 47. Dhindsa S, Miller MG, McWhirter CL, Mager DE, Ghanim H, Chaudhuri A, et al. Testosterone concentrations in diabetic and nondiabetic obese men. *Diabetes Care.* 2010; 33:1186–92. [PubMed: 20200299]

48. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, et al. Body mass index and risk of prostate cancer in U.S. health professionals. *J Natl Cancer Inst.* 2003; 95:1240–4. [PubMed: 12928350]
49. Jayachandran J, Bañez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. *Cancer.* 2009; 115:5263–71. [PubMed: 19670453]
50. Lonergan PE, Tindall DJ. Androgen receptor signaling in prostate cancer development and progression. *J Carcinog.* 2011; 10:20. [PubMed: 21886458]
51. Farooqi IS, O’Rahilly S. Leptin: a pivotal regulator of human energy homeostasis. *Am J Clin Nutr.* 2009; 89:980S–984S. [PubMed: 19211814]
52. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. *J Nutr Biochem.* 2009; 20:831–9. [PubMed: 19716279]
53. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance. *J Clin Endocrinol Metab.* 2001; 86:1930–35. [PubMed: 11344187]
54. Stefan N, Vojarova B, Funahashi T, Matsuzawa Y, Weyer C, Lindsay RS, et al. Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in human. *Diabetes.* 2002; 50:1884–88. [PubMed: 12031977]
55. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. *Endocr Regul.* 2009; 43:157–68. [PubMed: 19908934]
56. Housa D, Housová J, Vernerová Z, Haluzík M. Adipocytokines and cancer. *Physiol Res.* 2006; 55:233–44. [PubMed: 16238454]
57. Hoda MR, Keely SJ, Bertelsen LS, Junger WG, Dharmasena D, Barrett KE. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. *Br J Surg.* 2007; 94:346–54. [PubMed: 17212381]
58. Ogunwobi OO, Beales IL. The anti-apoptotic and growth stimulatory actions of leptin in human colon cancer cells involves activation of JNK mitogen activated protein kinase, JAK2 and PI3 kinase/Akt. *Int J Colorectal Dis.* 2007; 22:401–9. [PubMed: 16912864]
59. Saxena NK, Vertino PM, Anania FA, Sharma D. Leptin-induced growth stimulation of breast cancer cells involves recruitment of histone acetyltransferases and mediator complex to cyclin d1 promoter via activation of stat3. *J Biol Chem.* 2007; 282:13316–25. [PubMed: 17344214]
60. Sharma D, Saxena NK, Vertino PM, Anania FA. Leptin promotes the proliferation response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. *Endocr Relat Cancer.* 2006; 13:629–40. [PubMed: 16728588]
61. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. *J Biol Chem.* 2003; 278:42660–7. [PubMed: 12902351]
62. Garofalo C, Surmacz E. Leptin and cancer. *J Cell Physiol.* 2006; 207:12–22. [PubMed: 16110483]
63. Knight BB, Oprea-Illies GM, Nagalingam A, Yang L, Cohen C, Saxena NK, et al. Survivin upregulation, dependent on leptin-EGFR-Notch1 axis, is essential for leptin-induced migration of breast carcinoma cells. *Endocr Relat Cancer.* 2011; 18:413–28. [PubMed: 21555376]
64. Rene Gonzalez R, Watters A, Xu Y, Singh UP, Mann DR, Rueda BR, et al. Leptin-signaling inhibition results in efficient anti-tumor activity in estrogen receptor positive or negative breast cancer. *Breast Cancer Res.* 2009; 11:R36. [PubMed: 19531256]
65. Zheng Q, Dunlap SM, Zhu J, Downs-Kelly E, Rich J, Hursting SD, et al. Leptin deficiency suppresses MMTV-Wnt-1 mammary tumor growth in obese mice and abrogates tumor initiating cell survival. *Endocr Relat Cancer.* 2011; 18:491–503. [PubMed: 21636700]
66. Lautenbach A, Budde A, Wrann CD, Teichmann B, Vieten G, Karl T, et al. Obesity and the associated mediators leptin, estrogen and IGF-I enhance the cell proliferation and early tumorigenesis of breast cancer cells. *Nutr Cancer.* 2009; 61:484–91. [PubMed: 19838920]

67. Endo H, Hosono K, Uchiyama T, Sakai E, Sugiyama M, Takahashi H, et al. Leptin acts as a growth factor for colorectal tumours at stages subsequent to tumour initiation in murine colon carcinogenesis. *Gut*. 2011; 60:1363–71. [PubMed: 21406387]
68. Ribeiro AM, Andrade S, Pinho F, Monteiro JD, Costa M, Lopes C, et al. Prostate cancer cell proliferation and angiogenesis in different obese mice models. *Int J Exp Pathol*. 2010; 91:374–86. [PubMed: 20666851]
69. Tamakoshi K, Toyoshima H, Wakai K, Kojima M, Suzuki K, Watanabe Y, et al. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. *Oncology*. 2005; 68:454–61. [PubMed: 16020976]
70. Chia VM, Newcomb PA, Lampe JW, White E, Mandelson MT, McTiernan A, et al. Leptin concentrations, leptin receptor polymorphisms, and colorectal adenoma risk. *Cancer Epidemiol Biomarkers Prev*. 2007; 16:2697–703. [PubMed: 18086776]
71. Stattin P, Lukanova A, Biessy C, Söderberg S, Palmqvist R, Kaaks R, et al. Obesity and colon cancer: does leptin provide a link? *Int J Cancer*. 2004; 109:149–52. [PubMed: 14735482]
72. Wu MH, Chou YC, Chou WY, Hsu GC, Chu CH, Yu CP, et al. Circulating levels of leptin, adiposity and breast cancer risk. *Br J Cancer*. 2009; 100:578–82. [PubMed: 19223908]
73. Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. *Int J Cancer*. 1999; 80:523–6. [PubMed: 9935151]
74. Stattin P, Soderberg S, Biessy C, Lenner P, Hallmans G, Kaaks R, et al. Plasma leptin and breast cancer risk: a prospective study in northern Sweden. *Breast Cancer Res Treat*. 2004; 86:191–6. [PubMed: 15567935]
75. Harris HR, Tworoger SS, Hankinson SE, Rosner BA, Michels KB. Plasma leptin levels and risk of breast cancer in premenopausal women. *Cancer Prev Res*. 2011; 4:1449–56.
76. Petridou E, Belechri M, Dessypris N, Koukoulomatis P, Diakomanolis E, Spanos E, et al. Leptin and body mass index in relation to endometrial cancer risk. *Ann Nutri Metab*. 2002; 46:147–51.
77. Cymbaluk A, Chudecka-Głaz A, Rzepka-Górska I. Leptin levels in serum depending on Body Mass Index in patients with endometrial hyperplasia and cancer. *Eur J Obstet Gynecol Reprod Biol*. 2008; 136:74–7. [PubMed: 17007993]
78. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. *Clin Chem*. 2010; 56:34–43. [PubMed: 19910504]
79. Baillargeon J, Platz EA, Rose DP, Pollock BH, Ankerst DP, Haffner S, et al. Obesity, adipokines, and prostate cancer in a prospective population-based study. *Cancer Epidemiol Biomarkers Prev*. 2006; 15:1331–5. [PubMed: 16835332]
80. Hsing AW, Chua S Jr, Gao YT, Gentszchein E, Chang L, Deng J, et al. Prostate cancer risk and serum levels of insulin and leptin: a population-based study. *J Natl Cancer Inst*. 2001; 93:783–9. [PubMed: 11353789]
81. López Fontana CM, Maselli ME, Pérez Elizalde RF, Di Milta Mónaco NA, Uvilla Recupero AL, López Laur JD. Leptin increases prostate cancer aggressiveness. *J Physiol Biochem*. 2011; 67:531–8. [PubMed: 21559935]
82. Yamaji T, Iwasaki M, Sasazuki S, Tsugane S. Interaction between adiponectin and leptin influences the risk of colorectal adenoma. *Cancer Res*. 2010; 70:5430–7. [PubMed: 20516125]
83. Kelesidis I, Kelesidis T, Mantzoros CS. Adiponectin and cancer: a systemic review. *Br J Cancer*. 2006; 94:1221–5. [PubMed: 16570048]
84. Cong L, Gasser J, Zhao J, Yang B, Li F, Zhao AZ. Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL95 2. *Endocr Relat Cancer*. 2007; 14:713–20. [PubMed: 17914101]
85. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. *J Clin Endocrinol Metab*. 2007; 92:1041–8. [PubMed: 17192291]
86. Nakayama S, Miyoshi Y, Ishihara H, Noguchi S. Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. *Breast Cancer Res Treat*. 2008; 112:405–10. [PubMed: 18163210]

87. Arditi JD, Venihaki M, Karalis KP, Chrousos GP. Antiproliferative effect of adiponectin on MCF7 breast cancer cells: a potential hormonal link between obesity and cancer. *Horm Metab Res.* 2007; 39:9–13. [PubMed: 17226107]
88. Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. *Mol Endocrinol.* 2010; 24:1441–52. [PubMed: 20444885]
89. Bub JD, Miyazaki T, Iwamoto Y. Adiponectin as a growth inhibitor in prostate cancer cells. *Biochem Biophys Res Commun.* 2006; 340:1158–66. [PubMed: 16403434]
90. Wang Y, Lam KS, Xu JY, Lu G, Xu LY, Cooper GJ, et al. Adiponectin inhibits cell proliferation by interacting with several growth factors in an oligomerization-dependent manner. *J Biol Chem.* 2005; 280:18341–7. [PubMed: 15734737]
91. Bråkenhielm E, Veitonmäki N, Cao R, Kihara S, Matsuzawa Y, Zhivotovsky B, et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. *Proc Natl Acad Sci.* 2004; 101:2476–81. [PubMed: 14983034]
92. Fenton JI, Birmingham JM, Hursting SD, Hord NG. Adiponectin blocks multiple signaling cascades associated with leptin-induced cell proliferation in Apc Min/+ colon epithelial cells. *Int J Cancer.* 2008; 122:2437–45. [PubMed: 18338750]
93. Fenton JI, Birmingham JM. Adipokine regulation of colon cancer: adiponectin attenuates interleukin-6-induced colon carcinoma cell proliferation via STAT-3. *Mol Carcinog.* 2010; 49:700–9. [PubMed: 20564347]
94. Ealey KN, Archer MC. Elevated circulating adiponectin and elevated insulin sensitivity in adiponectin transgenic mice are not associated with reduced susceptibility to colon carcinogenesis. *Int J Cancer.* 2009; 124:2226–30. [PubMed: 19123482]
95. Nishihara T, Baba M, Matsuda M, Inoue M, Nishizawa Y, Fukuhara A, et al. Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice. *World J Gastroenterol.* 2008; 14:6473–80. [PubMed: 19030198]
96. Landskroner-Eiger S, Qian B, Muise ES, Nawrocki AR, Berger JP, Fine EJ, et al. Proangiogenic contribution of adiponectin toward mammary tumor growth in vivo. *Clin Cancer Res.* 2009; 15:3265–76. [PubMed: 19447867]
97. Denzel MS, Hebbard LW, Shostak G, Shapiro L, Cardiff RD, Ranscht B. Adiponectin deficiency limits tumor vascularization in the MMTV-PyV-mT mouse model of mammary cancer. *Clin Cancer Res.* 2009; 15:3256–64. [PubMed: 19447866]
98. Tian YF, Chu CH, Wu MH, Chang CL, Yang T, Chou YC, et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. *Endocr Relat Cancer.* 2007; 14:669–77. [PubMed: 17914097]
99. Miyoshi Y, Funahashi T, Kihara S, Taguchi T, Tamaki Y, Matsuzawa Y, et al. Association of serum adiponectin levels with breast cancer risk. *Clin Cancer Res.* 2003; 9:5699–704. [PubMed: 14654554]
100. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, et al. Adiponectin and breast cancer risk. *J Clin Endocrinol Metab.* 2004; 89:1102–7. [PubMed: 15001594]
101. Tworoger SS, Eliassen AH, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. *J Clin Endocrinol Metab.* 2007; 92:1510–6. [PubMed: 17213279]
102. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. *J Clin Oncol.* 2011; 29:32–9. [PubMed: 21115858]
103. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. *J Clin Endocrinol Metab.* 2007; 92:255–63. [PubMed: 17062769]
104. Petridou E, Mantzoros C, Dessypris N, Koukoulomatis P, Addy C, Voulgaris Z, et al. Plasma adiponectin concentrations in relation to endometrial cancer: a case-control study in Greece. *J Clin Endocrinol Metab.* 2003; 88:993–7. [PubMed: 12629074]
105. Soliman PT, Wu D, Tortolero-Luna G, Schmeler KM, Slomovitz BM, Bray MS, et al. Association between adiponectin, insulin resistance, and endometrial cancer. *Cancer.* 2006; 106:2376–81. [PubMed: 16639730]

106. Xu XT, Xu Q, Tong JL, Zhu MM, Huang ML, Ran ZH, et al. Meta-analysis: circulating adiponectin levels and risk of colorectal cancer and adenoma. *J Dig Dis.* 2011; 12:234–44. [PubMed: 21791018]
107. Michalakis K, Williams CJ, Mitsiades N, Blakeman J, Balafouta-Tselenis S, Giannopoulos A, et al. Serum adiponectin concentrations and tissue expression of adiponectin receptors are reduced in patients with prostate cancer: a case control study. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:308–13. [PubMed: 17301264]
108. Li H, Stampfer MJ, Mucci L, Rifai N, Qiu W, Kurth T, et al. A 25-year prospective study of plasma adiponectin and leptin concentrations and prostate cancer risk and survival. *Clin Chem.* 2010; 56:34–43. [PubMed: 19910504]
109. Garcia JA, Danielpour D. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies. *Mol Cancer Ther.* 2008; 7:1347–54. [PubMed: 18566209]
110. Kopelovich L, Fay JR, Sigman CC, Crowell JA. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention. *Cancer Epidemiol Biomarkers Prev.* 2007; 16:1330–40. [PubMed: 17626998]
111. Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, et al. Rapamycin extends maximal lifespan in cancer-prone mice. *Am J Pathol.* 2010; 176:2092–7. [PubMed: 20363920]
112. Granville CA, Warfel N, Tsurutani J, Hollander MC, Robertson M, Fox SD, et al. Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. *Clin Cancer Res.* 2007; 13:2281–9. [PubMed: 17404113]
113. Yan Y, Wang Y, Tan Q, Hara Y, Yun TK, Lubet RA, et al. Efficacy of polyphenon E, red ginseng, and rapamycin on benzo(a)pyrene-induced lung tumorigenesis in A/J mice. *Neoplasia.* 2006; 8:52–8. [PubMed: 16533426]
114. Raimondi AR, Molinolo A, Gutkind JS. Rapamycin prevents early onset of tumorigenesis in an oral-specific K-ras and p53 two-hit carcinogenesis model. *Cancer Res.* 2009; 69:4159–66. [PubMed: 19435901]
115. Liu M, Howes A, Lesperance J, Stallcup WB, Hauser CA, Kadoya K, et al. Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. *Cancer Res.* 2005; 65:5325–36. [PubMed: 15958580]
116. Blando J, Portis M, Benavides F, Alexander A, Mills G, Dave B, et al. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR dependent growth. *Am J Pathol.* 2009; 174:1869–1879. [PubMed: 19395652]
117. Amornphimoltham P, Leelahavanichkul K, Molinolo A, Patel V, Gutkind JS. Inhibition of Mammalian target of rapamycin by rapamycin causes the regression of carcinogen-induced skin tumor lesions. *Clin Cancer Res.* 2008; 14:8094–101. [PubMed: 19073969]
118. Checkley LA, Rho O, Moore T, Hursting S, DiGiovanni J. Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate. *Cancer Prev Res.* 2011; 4:1011–20.
119. Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, et al. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. *Cancer Prev Res.* 2008; 1:65–76.
120. Memmott RM, Dennis PA. Akt-dependent and independent mechanism of mTOR regulation in cancer. *Cell Signal.* 2009; 21:656–664. [PubMed: 19166931]
121. Lindsley JE, Rutter J. Nutrient sensing and metabolic decisions. *Comp Biochem Physiol B Biochem Mol Biol.* 2004; 139:543–59. [PubMed: 15581787]
122. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, et al. Metformin suppresses intestinal polyp growth in ApcMin/+ mice. *Cancer Sci.* 2008; 99:2136–41. [PubMed: 18803638]
123. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F, et al. Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. *Cancer Res.* 2007; 67:6745–52. [PubMed: 17638885]

124. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL, et al. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice. *Biochem J*. 2008; 412:211–21. [PubMed: 18387000]
125. Gallagher EJ, Leroith D. Diabetes, cancer, and metformin: connections of metabolism and cell proliferation. *Ann N Y Acad Sci*. 2011; 1243:54–68. [PubMed: 22211893]
126. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. *J Clin Invest*. 2003; 112:1796–808. [PubMed: 14679176]
127. Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al. Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans. *J Lipid Res*. 2005; 46:2347–55. [PubMed: 16150820]
128. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. *Annu Rev Physiol*. 2010; 72:219–46. [PubMed: 20148674]
129. Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-alpha and IL-6. *Diabetes Res Clin Pract*. 2005; 69:29–35. [PubMed: 15955385]
130. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. *Gastroenterol*. 2007; 132:2169–80.
131. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. *Cell*. 2010; 140:197–208. [PubMed: 20141834]
132. Wu Y, Shang X, Sarkissyan M, Slamon D, Vadgama JV. FOXO1A is a target for HER2-overexpressing breast tumors. *Cancer Res*. 2010; 70:5475–85. [PubMed: 20551062]
133. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. *Cytokine Growth Factor Rev*. 2010; 21:11–9. [PubMed: 20018552]
134. Ye J, Keller JN. Regulation of energy metabolism by inflammation: a feedback response in obesity and calorie restriction. *Aging*. 2010; 2:361–8. [PubMed: 20606248]
135. Baker RG, Hayden MS, Ghosh S. NF- κ B, inflammation, and metabolic disease. *Cell Metabolism*. 2011; 13:11–22. [PubMed: 21195345]
136. Dolcet X, Llobet D, Pallares J, Matias-Guiu X. NF-kB in development and progression of human cancer. *Virchows Arch*. 2005; 446:475–82. [PubMed: 15856292]
137. Kim DH, Kim JY, Yu BP, Chung HY. The activation of NF-kappaB through Akt-induced FOXO1 phosphorylation during aging and its modulation by calorie restriction. *Biogerontology*. 2008; 9:33–47. [PubMed: 17972158]
138. Carroll KK. Dietary Fats and Cancer. *Am J Clin Nutr*. 1991; 53:1064S–67S. [PubMed: 2012020]
139. Rose DP. Dietary Fatty Acids and Cancer. *Am J Clin Nutr*. 1997; 66(suppl):998S–1003S. [PubMed: 9322580]
140. Kushi L, Giovannucci E. Dietary Fat and Cancer. *Am J Med*. 2002; 113(Suppl 9B):63S–70S. [PubMed: 12566141]
141. Pierce JP, Natarajan L, Caan BJ, Parker BA, Greenberg R, Flatt SW, et al. Influence of a Diet Very High in Vegetables, Fruit, and Fiber and Low in Fat on Prognosis Following Treatment for Breast Cancer. *JAMA*. 2007; 298:289–98. [PubMed: 17635889]
142. Chlebowski RT, Blackburn GL, Thomson CA, Nixon DW, Shapiro A, Hoy MK, et al. Dietary Fat Reduction and Breast Cancer Outcomes: Interim Efficacy Results from the Women's Intervention Nutrition Study. *J Natl Cancer Inst*. 2006; 98:1767–76. [PubMed: 17179478]
143. Pierce JP. Diet and Breast Cancer Prognosis: Making Sense of the WHEL and WINS Trials. *Curr Opin Obstet Gynecol*. 2009; 21:86–91. [PubMed: 19130632]
144. Singer JB, Hill AE, Burrage LC, Olszens KR, Song J, Justice M, et al. Genetic dissection of complex traits with chromosome substitution strains of mice. *Science*. 2004; 304:445–48. [PubMed: 15031436]
145. Doerner SK, Leung ES, Berger NA, Nadeau JH. High dietary fat promotes inflammation and intestinal neoplasia, independently of diet-induced obesity, in B6.ApcMin/+ congenic-consomic mouse strains. *Proc AACR*. 2011:178.

146. Prentice RL, Caan B, Chlebowski RT, Patterson R, Kuller LH, Ockene JK, et al. Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. *JAMA*. 2006; 295:629–42. [PubMed: 16467232]
147. Prentice RL, Thomson CA, Caan B, Hubbell FA, Anderson GL, Beresford SA, et al. Low-fat dietary pattern and cancer incidence in the Women's Health Initiative Dietary Modification Randomized Controlled Trial. *J Natl Cancer Inst*. 2007; 99:1534–43. [PubMed: 17925539]
148. Friedenreich CM, Neilson HK, Lynch BM. State of the epidemiological evidence on physical activity and cancer prevention. *Eur J Cancer*. 2010; 46:2593–604. [PubMed: 20843488]
149. Zhu Z, Jiang W, Zacher JH, Neil ES, McGinley JN, Thompson HJ. Effects of Energy Restriction and Wheel Running on Mammary Carcinogenesis and Host Systemic Factors in a Rat Model. *Cancer Prev Res*. 2012; 5:414–22.
150. Silveira EM, Rodrigues MF, Krause MS, Vianna DR, Almeida BS, Rossato JS, Oliveira LP Jr, Curi R, deBittencourt PI Jr. Acute exercise and oxidative stress: Acute exercise stimulates macrophage function: possible role of NF-kappaB Pathways. *Cell Biochem Funct*. 2007; 25:63–73. [PubMed: 16906627]
151. Walsh NP, Gleeson M, Shephard JR, Gleeson M, Woods JA, Bishop NC, et al. Position statement. Part one: Immune function and exercise. *Exerc Immunol Rev*. 2011; 17:6–63. [PubMed: 21446352]
152. Padovani M, Lavigne JA, Chandramouli GV, Perkins SN, Barrett JC, Hursting SD, et al. Distinct effects of calorie restriction and exercise on mammary gland gene expression in C57BL/6 mice. *Cancer Prev Res*. 2009; 2:1076–87.
153. Imayama I, Ulrich CM, Alfano CM, Wang C, Xiao L, Wener MH, et al. Effects of a Caloric Restriction Weight Loss Diet and Exercise on Inflammatory Biomarkers in Overweight/Obese Postmenopausal Women: A Randomized Controlled Trial. *Cancer Res*. 2012; 72:2314–26. [PubMed: 22549948]
154. Campbell KL, Foster-Schubert KE, Alfano CM, Wang CC, Wang CY, Duggan CR, et al. Reduced-Calorie Dietary Weight Loss, Exercise, and Sex Hormones in Postmenopausal Women: Randomized Controlled Trial. *J Clin Oncol*. 2012; 30:2314–26. [PubMed: 22614972]
155. He C, Bassik MC, Moresi V, Sun K, Wei Y, Zou Z, et al. Exercise-induced BCL2-regulated autophagy is required for muscle glucose homeostasis. *Nature*. 2012; 18;481:511–5.
156. Schepers AG, Snippert HJ, Stange DE, van den Born M, van Es JH, van de Wetering M, et al. Lineage tracing reveals Lgr5+ stem cell activity in mouse intestinal adenomas. *Science*. 2012; 337:730–35. [PubMed: 22855427]
157. Dunlap SM, Chao LJ, Nogueira L, Usary J, Perou CM, Varticovski L, et al. Obesity enhances epithelial-to-mesenchymal transition and tumor progression in murine claudin-low and basal-like mammary tumor models. *Cancer Prev Res*. 2012; 5:930–42.
158. Kakarala M, Brenner DE, Korkaya H, Cheng C, tazi K, Ginestier C, et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. *Breast Cancer Res Treat*. 2010; 122:777–85. [PubMed: 19898931]
159. Kakarala M, Wicha MS. Implications of the cancer stem cell hypothesis for breast cancer prevention and therapy. *J Clin Oncol*. 2008; 26:2813–20. [PubMed: 18539959]
160. Finkelstein EA, Khavjou OA, Thompson H, Trogdon, Pan L, Sherry B, et al. Obesity and Severe Obesity Forecasts Through 2030. *Am J Prev Med*. 2012; 42:563–70. [PubMed: 22608371]
161. Cowey S, Hardy RW. The metabolic syndrome: A high-risk state for cancer? *Am J Pathol*. 2006; 169:1505–22. [PubMed: 17071576]




Figure 1. Peptide Growth Factors, Adipokines, Nutrients and Other Putative Factors Involved in Regulating Obesity Related Carcinogenesis. Adapted with permission from Nock and Berger (12) and Cowley and Hardy (161). Factors denoted in *bold red text* are core features of the Metabolic Syndrome. Factors denoted in *bold blue text* are additional features that may also be components of the Metabolic Syndrome. Abbreviations used: CRP, C-reactive protein; FFA, free fatty acids; IGF-1, insulin-like growth factor 1; IGFBP, insulin-like growth factor-binding protein; IL-6, interleukin-6; IL- β , interleukin-1 β ; MAC, macrophage; MCP-1, monocyte chemoattractant protein 1; Mito, mitochondria; PAI-1, plasminogen activator inhibitor-1; ROS, reactive oxygen species; SHBG, steroid hormone-binding globulin; TG, triglycerides; TNF- α , tumor necrosis factor α ; VEGF, vascular endothelial growth factor.




Figure 2. Intracellular Pathways Mediating Obesity, Energy Balance and Cancer Intracellular Pathways of Growth Factors Involved in Obesity Associated Cancer Promotion and Progression. Adapted with permission from Nock and Berger (12) and Moore et al (119).

Table 1**Obstacles to Prevention of Obesity Associated Cancers**

Obstacles to Disrupting Obesity Promotion of Cancer	
1	Multiplicity of obesity driven extracellular hormone and growth factors promoting tumor cell growth, e.g., insulin, IGF-1, leptin, estradiol
2	Multiplicity of obesity driven extracellular inflammatory factors, e.g., IL-1 β , IL-6, TNF α
3	Receptor hybridization, cross-talk and multiplicity, e.g., insulin receptor, IGF receptor, leptin receptor
4	Multiplicity and cross-talk among intracellular pathways activated by obesity mediators, e.g., PI3K-Akt-mTOR, JAK2-STAT3-MAPK, NANOG-SOX, EGFR-Notch1-Survivin
5	Multiplicity of cellular targets, e.g., cancer cells, cancer stem cells, tumor microenvironment, vascular endothelium
Obstacles to Obesity Control	
6	Genetic programming for energy storage
7	Abundance of high energy density foods
8	Poor adherence to caloric restriction
9	Inadequate sleep
10	Sedentary lifestyles and proliferation of energy saving devices
11	Built environment impediments to physical activity
12	Cost and accessibility of exercise equipment and programs
13	Absence of effective pharmacologic interventions
14	High cost and consequences of bariatric surgery
